M aany clinical studies, both of patients with angina pectorisl-4 and of patients with heart failure,5-7 have demonstrated that continuous administration of organic nitrates leads to a decrease of their therapeutic efficacy. Nevertheless, there is still no general agreement concerning the relative susceptibility of the arterial and venous system to the development of nitrate tolerance in humans. In 1975, Zelis and Mason8 demonstrated venous but not arterial cross-tolerance to the effects of isosorbide dinitrate and nitroglycerin in six normal volunteers. Subsequent studies, however, reported different results, either showing partial tolerance in both arterial and venous circulations9 or demonstrating significant attenuation to the arterial and not to the venous or pulmonary vascular effects of isosorbide dinitrate.10 More recently, the greater and more frequent attenuation of nitroglycerin action in the venous bed has been reemphasized in nine patients with congestive heart failure."' Accordingly, the aim of our study was to assess the specific responses to a 24-hour continuous nitroglycerin infusion of the peripheral arterial and venous vascular circulations in humans. In addition, because intracellular sulfhydryl groups are necessary for nitrate-induced vasodilation12"3 and a reduction in tissue content of these groups is thought to be one of the primary mechanisms responsible for nitrate tolerance,14"5 we also investigated the effects of N-acetylcysteine, a sulfhydryl-containing compound, on the arterial and venous tolerant and nontolerant circulations.
Methods

Patients
Twenty patients with coronary artery disease entered and completed the investigation (18 
Variability of Plethysmographic Determinations
To assess the reproducibility of plethysmographic determinations of venous volume and forearm vascular resistance in our laboratory, plethysmography was performed twice, 1 hour apart, in seven control subjects; replicate measurements 24 hours apart were also obtained in another cohort of seven subjects. Replicate measurements of forearm vascular resistance yielded a mean difference of -1.16±0.75 mm Hg/ml/100 ml/min mean at 1 hour and -0.83±0.80 mm Hg/ml/100 ml/min at 24-hour determinations. Venous volume measurements showed a mean difference of -0.04±0.166 ml/ 100 ml at 1 hour and 0.23±0.17 ml/100 ml at 24-hour evaluations. Individual changes in venous volume or vascular resistance were considered significant only when exceeding 2 SD of 1-hour or 24-hour variability. We therefore considered "responder" to nitroglycerin and included in the study only 20 of 29 patients who had, at peak nitroglycerin titration, a venous volume increase of at least 0.33 ml/100 ml or a vascular resistance decrease of at least 1.5 mm Hg/ml/100 ml/min.
Tolerance was defined after 24-hour infusion when a venous volume decrease of at least 0.34 ml/100 ml or a vascular resistance increase of at least 1.6 mm Hg/ml/ 100 ml/min was observed. Protocol
After baseline measurements of heart rate, blood pressure, forearm blood flow, and venous volume, an intravenous infusion of nitroglycerin was started at a rate of 10 ,ug/min, and the rate was increased approximately every 5-10 minutes by 
Forearm Venous Volume and Vascular Resistance
Nitroglycerin titration resulted in an average 26% increase in venous volume (from 2.69±1.08 to 3.42±+1.22 ml/100 ml, p<0.01). However, at 24 hours, 48% of this increase was lost, and values were significantly lower than at peak titration (3.07±1.09 ml/100 ml, p<0.05). After N-acetylcysteine, venous volume increased again significantly, reaching values similar to those of peak titration (3.56±1.25 ml/100 ml, p<0.01 versus 24 hours). Forearm vascular resistance decreased by an average of 16% at peak nitroglycerin titration (from 29.8+±12.6 to 24.9±11.3 mm Hg/mI/00l ml/min, p<0.01). Vascular resistance was slightly lower at 24 hours (23.1±8.8 mmHg/ml/100 ml, NS versus peak titration) and did not change significantly after N-acetylcysteine (21.4±+8.4 mm Hg/ml/100 ml/min, NS versus 24 hours). Forearm resistance data apply to 16 of 20 patients in whom a significant decline was observed after nitroglycerin titration. See Figure 2 .
N-Acetylcysteine
To better define the effects of N-acetylcysteine, we evaluated the response to the sulfhydryl group Ten of 20 patients in whom venous volume at 24 hours was significantly lower than at peak nitroglycerin titration were considered as having "venous tolerance": In these patients, venous volume increased significantly after N-acetylcysteine (from 2.7 +0.8 to 3.5± 1.1 ml/100 ml, p<0.01), comparable to the peak titration level (3.5 ± 1.3 ml/100 ml); a significant response to N-acetylcysteine was observed in all patients. In the remaining 10 patients, no change occurred after N-acetylcysteine (from 3.5±1.2 to 3.6±1.4 ml/100 ml, NS); in this subgroup, a significant response to N-acetylcysteine was observed in two of 10 patients (Figure 3) . No ips to the disulfides them just as reOur observations on the efficacy of N-acetylcysteine in reversing venous tolerance and its lack of hemodynamic effects in nontolerant arterial and venous circulations are seemingly in contrast with previous studies indicating potentiation of nitroglycerin action with this sulfhydryl group donor. Actually, much of this discrepancy might be attributed to differences in the protocol of N-acetylcysteine administration. Pretreatment with N-acetylcysteine potentiates the effects of a subsequent infusion of nitroglycerin: The increase in coronary flow25 or the decrease in systemic blood pressure and pulmonary capillary wedge pressure26 in response to a fixed dose of nitroglycerin was significantly higher after N-acetylcysteine than under control conditions. However, in another study with protocol similar to ours, N-acetylcysteine was added to a previous 24-hour infusion of nitroglycerin,27 only reversal of nitrate tolerance without potentiating effects was observed; however, these authors did not carry out a separate analysis in patients who developed and who did not develop nitrate tolerance. To further complicate the problem, only partial reversal of tolerance was observed by Packer and coworkers6 when N-acetylcysteine was administered in eight nitrate-tolerant patients with congestive heart failure. Experimental studies are still unable, at the moment, to explain the conflicting results obtained in humans. The incubation of tolerant arterial vascular rings with different sulfhydryl donors produced reversal of tolerance in most14' 5but not all28 studies; a nonspecific potentiation of nitroglycerin action has also been demonstrated,29 and it has been postulated to occur at an extracellular site.30 Clearly, one should take into account that the interactions between organic nitrates and sulfhydryl groups are so complex and still incompletely elucidated as to why different results have been obtained when different patients and different doses and schedules of N-acetylcysteine administration have been used in human studies.
Conclusions
The results of this study indicate that the susceptibility to the development of nitroglycerin tolerance in humans is higher in the venous than in the arterial circulation, and that venous tolerance can be rapidly reversed by the administration of a sulfhydryl group donor like N-acetylcysteine. We emphasize the fact that in clinical studies aimed at evaluating the attenuation of the beneficial action of nitrates and the possibility to reverse tolerance with the association of sulfhydryl group donors (or other compounds), a physiopathological interpretation of the data is impossible if we do not explore the effects of these drugs on both the arterial and venous sides of the circulation.
